CoChat

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

Open access
Holmes, Gregory, Galitz, Lawrence, Hu, Peter, Lyness, William · 2005 · British Journal of Clinical Pharmacology
Cited by 86

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Aims: To assess the effects of body mass index, renal impairment (creatinine clearance), and hepatic impairment (Child‐Pugh Score) on the pharmacokinetics of insulin aspart. Methods: Pharmacokinetics of insulin aspart (injected subcutaneously in the abdomen immediately before a Boost® standardized meal) were characterized in: (1) diabetic subjects with four ranges of BMI values (n = 23); (2) diabetic subjects with varying degrees of renal impairment (normal, n = 6 vs. two ranges of impairment, n = 12); and (3) nondiabetic patients with varying degrees of hepatic impairment (normal, n = 6 vs. three ranges of impairment, n = 18). Results: There was no correlation between any pharmacokinetic variable and the degree of renal or hepatic impairment. Increasing obesity was associated with a decreased apparent clearance per kg body weight (β = −0.0005, SE = 0.0001; P = 0.002), an increased t½ (β = 3.513, SE = 1.636; P = 0.044), and an increased ln(AUC 0−360) and ln(AUC 0−1440) (β = 0.030, SE = 0.013; P = 0.032 and β = 0.039, SE = 0.0132; P = 0.006, respectively). However, obesity‐related changes were smaller than individual variations in parameters. Conclusions: Renal impairment, hepatic impairment, or BMI do not affect the pharmacokinetics of insulin aspart in a clinically significant manner. Abbreviations: AUC 0–1440, area under the plasma concentration curve; BMI, body‐mass index; CL cr, renal clearance of creatinine; CL/F, apparent clearance; CL/F/kg, body weight‐adjusted apparent clearance; Cmax, maximal plasma concentration; FBG, fasting blood glucose; GFR, glomerular filtration rate; HI, human insulin; MRT, mean residence time; PK, pharmacokinetics; t½, half life; tmax, time to maximum concentration; Vz/F, apparent volume of distribution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2005.02476.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 86

Metadata

Authors
Holmes, G., Galitz, L., Hu, P., & Lyness, W.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2005-08
Volume
60
Issue
5
Pages
469-476
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1999246346
Cited by
86
References
1
FWCI
0.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02476.x
The paper
Holmes, G., Galitz, L., Hu, P., & Lyness, W. (2005). Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02476.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.